A Drug Interaction Study to Assess the Effect of LY317615 on the Metabolic Pathway of Warfarin
Status:
Completed
Trial end date:
2012-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the effect of enzastaurin (LY317615), on a protein
(enzyme CYP2C9) which is involved in the metabolic pathway of warfarin in participants with
solid tumors or lymphomas. Information about any side effects that may occur will also be
collected. This is a drug interaction study so the treatment of the disease will not be the
main purpose of the study.
This is a Phase 1, open label, fixed sequence, 2 period study conducted in participants with
solid tumors or lymphomas. The duration of participation in this study will be up to
approximately 38 days not including screening, after which participants will be allowed to
continue receiving enzastaurin. There is no planned duration for the extension phase of this
study; participants will be allowed to continue to receive enzastaurin until fulfilling one
of the criteria for discontinuation, such as unacceptable toxicity or disease progression.